Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenfu Xiaozheng Decoction is a Traditional Chinese Medicine (TCM) herbal formula being investigated for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The decoction is formulated based on TCM principles to 'tonify the kidney and resolve stasis,' specifically targeting the pathogenesis of renal cyst formation and enlargement. It typically incorporates core herbs such as Ginseng and Aconite to support vital energy (Qi), alongside 'Xiaozheng' herbs intended to eliminate masses or cysts. In clinical research, it is often evaluated as an adjunctive therapy to vasopressin V2 receptor antagonists like tolvaptan to enhance therapeutic efficacy, reduce total kidney volume growth, and potentially mitigate the side effects of Western pharmacological treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenfu Xiaozheng Decoction.